Neverland
Reference number | |
Coordinator | Igeia Health Labs AB |
Funding from Vinnova | SEK 88 218 |
Project duration | September 2017 - December 2017 |
Status | Completed |
Venture | Bygginnovationen 2011-2014 |
Call | 2015-06960-en |
Purpose and goal
Sick leaves due to psychosomatic diseases is increasing. An important aspect of preventive work is to facilitate individuals to easily and quickly reduce stress levels. This project aims at developing a mobile lelaxation room that promotes health in the workplace. The aim of this project phase was to investigate market potential and customer wishes. The project has contributed to the fact that there is now a market analysis and a clear picture of the needs and perceptions of potential customers. In the project, a full-scale prototype has been developed that will be further developed.
Expected results and effects
This subproject has been an important step in investigating the concept´s market potential, which demonstrated the prerequisites for a commercially viable product. Analysis of needs and requests from potential end users and customers shows that the concept is sustainable and desirable, with some adjustments to meet the needs of location, user experience and accessibility. Prior to the next phase of production, detailed prototype testing in the test environment should be investigated. Several partners have been linked to the further development of products and concepts.
Planned approach and implementation
The project´s activities have focused on further development of the product in parallel with interaction with customers, end users and partners. In collaboration with new partners, the concept idea has been further developed through visualization, revision and validation in workshops and technical tests, including prototyping work. Customers and end users have contributed with insights about needs and wishes as well as perceptions of concepts and prototype sketches. Interaction with these groups has taken place through workshops, meetings and interviews in Q3 2017.